Psoriasis Latest News Archive

Psoriasis

Patient Needs, Treatment Goals in Psoriasis Vary by Gender and Age

By December 18, 2018

During consultation, physicians need to assess the best individual psoriasis treatment option based on the individual patient needs.

Psoriasis

Meta-Analyses Confirm Validity, Usefulness of Systemic Therapies for Psoriasis

By December 17, 2018

Researchers provide a summary and analysis of 2 recent network meta-analysis (NMA) studies that evaluated systemic therapies for moderate-to-severe psoriasis.

Psoriasis

Secukinumab Superior to Placebo for Treatment of Moderate to Severe Nail Psoriasis

By December 14, 2018

The ability of secukinumab vs placebo to clear nail psoriasis was evaluated using the Nail Psoriasis Severity Index.

Psoriasis

Clinical Response Evaluated After Withdrawal, Retreatment With Ixekizumab in Plaque Psoriasis

By December 13, 2018

Investigators evaluated the effect of ixekizumab withdrawal and retreatment in Japanese patients with plaque psoriasis in this single-arm open-label phase 3 study.

Psoriasis

New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Tx Option

By December 12, 2018

The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Psoriasis

Psoriasis Significantly Associated With Inflammatory Bowel Disease

By December 12, 2018

People with psoriasis may have an increased risk for inflammatory bowel disease. Gastroenterology consultation may be indicated when patients with psoriasis present with bowel symptoms.

Psoriasis

Ixekizumab Deemed Safe, Effective for Plaque Psoriasis in Real-World Study

By December 11, 2018

Similar to randomized clinical trials, real-life study complements safety and efficacy profiles of ixekizumab treatment in patients with plaque psoriasis.

Psoriasis

Psoriasis Linked With Higher Risk for Sexual Dysfunction

By December 10, 2018

People with psoriasis have physical and psychological comorbidities that are associated with a higher risk for sexual dysfunction.

Psoriasis

Effectiveness of Online vs In-Person Care for Adult Patients With Psoriasis

By December 06, 2018

Investigators examined whether patients benefited from interacting with their dermatologist online rather than in person to manage their psoriasis.

Psoriasis

Clinical Outcomes in Patients With Early-Onset vs Late-Onset Psoriasis

By December 06, 2018

Investigators examined patients with late-onset psoriasis who were treated with etanercept, infliximab, or methotrexate to see whether they were significantly more likely than patients with early-onset psoriasis to have a therapeutic response.

Psoriasis

Illuvinate System Now Available for Plaque Psoriasis Treatment

By December 05, 2018

The treatment is based on the Goeckerman regimen which dates back to the 1920s and involves applying coal tar to a patient's skin and exposing the skin to ultraviolet light.

Psoriasis

Etanercept May Be Effective in Plaque Psoriasis With Failed Apremilast Therapy

By November 30, 2018

In patients with moderate to severe plaque psoriasis, who have failed to respond to apremilast therapy, etanercept may represent an effective therapeutic option.

Psoriasis

Biologic Agents Used to Treat Patients With Psoriasis and HIV Infection

By November 30, 2018

Investigators evaluated the safety and effectiveness of conventional therapy with biologic immunosuppressive drugs to treat patients with HIV infection and psoriasis.

Psoriasis

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

By , Caleb Rans November 28, 2018

Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.

Psoriasis

Novel Scoring System Facilitates Access to Biologics in Psoriasis

November 27, 2018

A new scoring system that accounts for "not relevant" responses (NRRs) on the Dermatology Life Quality Index (DLQI) for patients with psoriasis is valid for avoiding bias and can improve access to biologics.

Psoriasis

Psychosocial Intervention Improves Anxiety and Quality of Life in Patients With Psoriasis

By November 27, 2018

A recent review found that existing psychosocial interventions using cognitive-behavioral and mindfulness-based approaches had a small but significant effect on quality of life and anxiety outcomes in patients with psoriasis.

Psoriasis

Effective Treatment of Psoriasis May Lead to Reversal of Alexithymia

By November 16, 2018

Alexithymia reversal was higher in patients who achieved control of their psoriasis, and reversal was associated with significant improvements in quality of life, anxiety, and depression.

Psoriasis

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

By Emily Pond November 16, 2018

Data show that filgotinib is effective for the treatment of active psoriatic arthritis.

Psoriasis

Gout Associated With Psoriatic Arthritis, Psoriasis in Adults

By Caleb Rans November 16, 2018

Data show an increased prevalence of psoriasis in patients with gout compared with patients without gout.

Psoriasis

New Topical Steroid Option for Plaque Psoriasis Soon to Be Available

By November 15, 2018

The approval was supported by data from 2 prospective, multicenter, randomized, double-blind clinical trials.

Psoriasis

Evidence Supporting Routine Joint Inflammation Screening in Skin Psoriasis Limited

By November 13, 2018

Prevalence of sacroiliac MRI changes was similar in patients and healthy controls for all lesion types.

Psoriasis

Computer-Guided PASI Score Technology Comparable to Physician Assessment

By November 12, 2018

Researchers performed automated total body imaging and digital image analysis to create an objective, computer-guided technology to evaluate patients' PASI score.

Psoriasis

Namilumab Ineffective in Treatment of Moderate to Severe Plaque Psoriasis

By November 05, 2018

Investigators examined the safety and efficacy of namilumab in patients with moderate to severe plaque psoriasis.

Psoriasis

Certolizumab Pegol Effective for Moderate to Severe Chronic Plaque Psoriasis

By November 01, 2018

Both doses of certolizumab resulted in good respond rates compared with placebo, regardless if participants were treated with biologics previously.

Psoriasis

Selective Inhibition of Tyrosine Kinase 2 Helps Clear Psoriasis

By October 31, 2018

Selective inhibition of TYK2 with an oral agent — BMS-986165 — at a dose of ≥3 mg per day has been associated with greater clearing of psoriasis.

Psoriasis

Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

By October 31, 2018

Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.

Psoriasis

Secukinumab Effective for Treatment of Refractory Plaque Psoriasis

By October 31, 2018

Human anti-interleukin-17A monoclonal antibody secukinumab has demonstrated utility for the treatment of patients with chronic plaque psoriasis.

Psoriasis

No Significant Risk for Atrial Fibrillation, CV Events in PsA Receiving Ustekinumab vs TNF Inhibitors

By October 26, 2018

The primary and secondary outcomes included incident AF or a composite CV event that included myocardial infarction, stroke, and coronary revascularization.

Psoriasis

Ilumya Now Available for the Treatment of Plaque Psoriasis

By October 25, 2018

Ilumya has been made available by Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis.

Psoriasis

Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis

By October 25, 2018

Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.

Psoriasis

Bryhali Lotion Gets Tentative Approval for Plaque Psoriasis

By October 19, 2018

The approval of Bryhali was based on data from 2 randomized, double-blind studies conducted in 430 patients with moderate to severe plaque psoriasis.

Psoriasis

Safety Outcomes Associated With Apremilast Use in Psoriasis

By October 19, 2018

Investigators examined long-term safety during weeks 16 to 52 of apremilast in patients with psoriasis.

Psoriasis

Aortic Vascular Inflammation Associated With Coronary Artery Disease in Psoriasis

By October 19, 2018

Aortic vascular inflammation is a potential precursor to early coronary artery disease in patients with psoriasis.

Psoriasis

Psoriasis Associated With Clinical Signs of Accelerated Atherosclerosis

By October 18, 2018

The findings could corroborate existing evidence on how changes in serum ACE, the renin-angiotensin system, and vascular endothelium metabolism may be linked to atherosclerosis in psoriasis.

Psoriasis

Halobetasol/Tazarotene Provides Relief for Moderate to Severe Psoriasis

By October 16, 2018

Investigators examine the efficacy and tolerability of halobetasol/tazarotene within the first 2 weeks of treatment.

Psoriasis

Halobetasol Propionate Lotion Shows Efficacy for Tx of Psoriasis

October 16, 2018

Halobetasol propionate 0.01 percent lotion appears safe and effective for the treatment of moderate-to-severe plaque psoriasis.

Psoriasis

TYK2 Inhibitor Clears Psoriasis Over 12 Weeks

October 15, 2018

Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks.

Psoriasis

Adjunctive Topical Foam Plus Biologics Effective for Refractory Psoriasis

By October 09, 2018

All participants had been treated with biologic therapies for more than 24 weeks and had not obtained adequate response.

Psoriasis

Guselkumab Effective for Long-Term Treatment of Moderate to Severe Psoriasis

By October 09, 2018

Sustained-response treatments are of great importance in chronic conditions like psoriasis.

Psoriasis

Risankizumab May Be More Effective Than Ustekinumab for Plaque Psoriasis

By Dermatology Advisor Contributing Writer October 08, 2018

Patients with moderate to severe plaque psoriasis from 2 replicate, phase 3, randomized, double-blind, placebo-controlled, and active comparator-controlled trials were included in the analysis.

Psoriasis

Alternative Medicines May Aid in the Treatment of Psoriasis

October 08, 2018

Some complementary and alternative medicines may be helpful in the treatment of psoriasis.

Psoriasis

Infliximab Linked to Increased Risk for Serious Infections in Psoriasis

By October 03, 2018

The investigators sought to compare the risk for serious infections linked with infliximab use in patients with chronic plaque psoriasis vs a cohort receiving nonbiologic systemic treatments.

Psoriasis

Pustular Psoriasis: Clinical and Genetic Differences Between Subtypes Revealed

By September 27, 2018

IL36RN disease alleles had a significant dose-dependent effect on age of onset of all types of pustular psoriasis.

Psoriasis

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

September 27, 2018

A lawsuit filed Tuesday in California claims that pharmaceutical company AbbVie used cash, gifts, and services to induce doctors to overprescribe the widely used drug Humira, ignoring the medicine's potentially lethal side effects.

Psoriasis

Psoriasis Not a Risk Factor for Cognitive Dysfunction and Dementia

By Dermatology Advisor Contributing Writer September 24, 2018

The study investigated the association between psoriasis and preclinical markers of dementia and the population's risk for dementia onset.

Psoriasis

Adalimumab Biosimilar Demonstrates Clinical Equivalence in Psoriasis Study

By September 17, 2018

The Phase 3 study (N=318) enrolled patients aged 18 to 78 years with moderate-to-severe chronic plaque psoriasis who had not previously received treatment with ≥1 biologic.

Psoriasis

CAM Therapies and Psoriasis: Which Treatments Are Effective?

By September 13, 2018

Evidence on the effectiveness of complementary and alternative medicine therapies in the treatment of plaque psoriasis was compiled in a new systematic review.

Psoriasis

Femoral Artery Atherosclerosis More Common in Psoriasis

By September 11, 2018

The results indicated that participants with psoriasis had a significantly higher prevalence of femoral plaques compared with control patients.

Psoriasis

Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb

September 10, 2018

Under Medicare Part D, out-of-pocket costs are similar for infliximab and its biosimilar infliximab-dyyb.

Psoriasis

Resubmitted Duobrii Lotion NDA for Plaque Psoriasis Accepted

By September 07, 2018

Its long-term safety was evaluated in a phase 3, multicenter, open-label study of 555 adults with moderate to severe plaque psoriasis.

Psoriasis

Psoriasis Treatment Effects Sustained With Topical Corticosteroid, Tazarotene Lotion

By August 29, 2018

At the conclusion of the 4-week posttreatment period, 38.2% of HP/TAZ-treated patients were considered treatment successes.

Psoriasis

Elevated Mortality Risk in Psoriasis May Be Associated With Comorbidities

By August 22, 2018

This increased burden of comorbidity may have implications for the increased risk for mortality reported among those with psoriasis.

Psoriasis

Inverse Link for Mediterranean Diet Score, Severe Psoriasis

August 14, 2018

Patients with severe psoriasis have low levels of adherence to the Mediterranean diet.

Psoriasis

Lower Real-World Drug Survival for Apremilast in Psoriasis vs Clinical Trials

By August 09, 2018

Having received prior treatment might have an effect on drug survival rates.

Psoriasis

Ixekizumab Superior to Ustekinumab for Clearing Psoriasis Plaques

August 09, 2018

Injection site reactions did occur more frequently in the ixekizumab group compared with the ustekinumab group.

Psoriasis

IDEOM Group Names 6 Core Domains for Psoriasis Clinical Trials

By August 02, 2018

The IDEOM group has determined 6 core domains that should be considered mandatory for all future clinical trials for psoriasis therapies.

Psoriasis

Prevalence of Psoriatic Arthritis Quantified in Patients With Psoriasis

By August 01, 2018

Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.

Psoriasis

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

By July 16, 2018

Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.

Psoriasis

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By July 13, 2018

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.

Psoriasis

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

By July 13, 2018

Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.

Psoriasis

More Research Needed on S aureus Colonization in Psoriasis

By July 05, 2018

Controlled studies to evaluate the benefits of a universal or targeted decolonization program in patients with psoriasis is warranted.

Psoriasis

Ixekizumab Effective for Long-Term Treatment of Plaque Psoriasis

By July 04, 2018

Similar response rates were observed in patients with baseline scalp, nail, or palmoplantar involvement.

Psoriasis

Antibiotic-Methotrexate Combo Leads to Serious Side Effects in RA Patient

By June 28, 2018

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of TS for a bacterial skin infection.

Psoriasis

Psoriasis Treatment With Biologics Often Requires Multiple Courses, Treatment Changes

By June 26, 2018

The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.

Psoriasis

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By June 18, 2018

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

Psoriasis

Many Psoriasis Patients Have Not Achieved Clear Skin, Despite Its Possibility

By June 15, 2018

Participants who did not have clear/almost clear skin reported that achieving clear/almost clear skin would open new possibilities, such as swimming, trying on new clothes, and meeting new people.

Psoriasis

Adalimumab Associated With Reduced Inflammation in Psoriasis

By June 15, 2018

Larger studies with more detailed phenotyping of vascular disease are warranted to evaluate the comparative differences in the effects of adalimumab and phototherapy that were observed in the current study.

Psoriasis

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

By June 13, 2018

Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.

Psoriasis

No Increased Risk for Liver Cirrhosis With Long-Term Methotrexate Use for Psoriasis

By June 11, 2018

Real-world data have demonstrated no rise in the development of incident liver cirrhosis among patients with psoriasis and either CHB or CHC who have received long-term MTX therapy.

Psoriasis

Apremilast Combination Therapy Helps Maintain Therapeutic Response in Psoriasis

By June 07, 2018

The use of apremilast in combination with biologic or systemic agents has been recommended for disease control in those patients with challenging psoriasis that cannot be controlled with the use of a single agent alone.

Psoriasis

New Biologic Treatment Option Approved for Patients With Plaque Psoriasis

June 04, 2018

The expanded approval was supported by findings from a Phase 3 clinical program (CIMPASI-1, CIMPASI-2, and CIMPACT), which enrolled ~1000 patients who were biologic-naive or biologic-experienced.

Psoriasis

Guselkumab Linked to Improvement in Anxiety, Depression Symptoms in Psoriasis

By June 01, 2018

At week 16, a significantly greater proportion of participants in the guselkumab group with baseline Hospital Anxiety and Depression Scale A (HADS-A) or HADS-D ≥8 scored HADS-A <8 or HADS-D <8 compared with participants in the placebo group.

Psoriasis

Certolizumab Looks Promising for Moderate to Severe Psoriasis

May 30, 2018

Twice-weekly certolizumab biologic appears to be both safe and effective for the treatment of moderate to severe chronic plaque psoriasis.

Psoriasis

Are Biologic Therapies for Psoriasis Associated With Increased Risk for Cardiovascular Events?

By May 24, 2018

Investigators sought to determine the risk for MI following hospital-diagnosed psoriasis compared with that in the general population in the eras preceding and following the introduction of biologic therapy.

Psoriasis

Taltz Label Updated to Include Data on Psoriasis Affecting Genital Area

By May 24, 2018

The approval was based on data from a randomized, placebo-controlled trial that included 149 adults with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a static Physician Global Assessment (sPGA) score of ≥3 (moderate psoriasis), a sPGA of Genitalia score of ≥3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for the treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.

Psoriasis

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

By May 24, 2018

The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.

Psoriasis

Supporting App Improves Treatment Adherence in Psoriasis

By May 22, 2018

The supporting app used by the participants in the intervention group provided them with daily reminders and informed them about whether they had applied their treatment.

Psoriasis

Clinical and Therapeutic Differences Between Linear and Classical Psoriasis

By May 18, 2018

Studies using molecular analysis to compare DNA samples might help to clarify the molecular basis of the psoriasis disease process and thus improve treatment efficacy.

Psoriasis

High-Dose Certolizumab Pegol Effective for Symptom Reduction in Chronic Plaque Psoriasis

By May 17, 2018

The investigators concluded that both certolizumab pegol treatment regimens improved the symptoms of psoriasis among the participants, with the greatest response observed at the higher dose.

Psoriasis

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

By May 11, 2018

The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.

Psoriasis

Psoriasis Negatively Affects Patient Sleep Quality

May 10, 2018

Patients with psoriasis commonly report poor sleep, with itch being the main predictor.

Psoriasis

TNF Inhibitors in Psoriasis Linked to Reduced Risk for Cardiovascular Events

By May 09, 2018

The investigators concluded that the use of TNFi therapy in patients with psoriasis may be beneficial for reducing cardiovascular outcomes.

Psoriasis

Psoriasis Patients Deemed Ineligible for Clinical Trials Often Have Worse Outcomes

By May 02, 2018

Clinical trial effectiveness and safety outcomes of biologic therapies for psoriasis do not represent real-world patients, especially those categorized as ineligible in the current study and who would have been excluded from such trials.

Psoriasis

Secukinumab for Severe Psoriasis Relapse After Brodalumab Discontinuation

By May 01, 2018

Investigators sought to determine whether secukinumab is effective for severe forms of plaque psoriasis after an abrupt discontinuation of brodalumab.

Psoriasis

Low Conversion Rate of Quantiferon-TB Test in TNF Inhibitor-Treated Patients

By April 30, 2018

Investigators sought to determine the rate of conversion of Quantiferon-TB Gold screening test in patients taking anti-TNF therapy.

Psoriasis

Risankizumab BLA Submitted for Moderate to Severe Plaque Psoriasis

By April 27, 2018

The BLA is supported by data from the global risankizumab Phase 3 psoriasis program evaluating more than 2,000 patients.

Psoriasis

Ustekinumab Linked to Decreased Systemic/Vascular Inflammation in Psoriasis

By April 27, 2018

Investigators sought to determine whether ustekinumab reduces vascular and systemic inflammation associated with cardiovascular disease and metabolic syndrome.

Psoriasis

Phone App Linked to Improved Psoriasis Treatment Adherence

April 26, 2018

A smartphone app is associated with improved short-term adherence to a cutaneous foam treatment for psoriasis.

Psoriasis

Ixekizumab Effective for Psoriasis Regardless of Psoriatic Arthritis Status

By April 17, 2018

The investigators concluded that ixekizumab therapy is a safe and effective treatment for the improvement of efficacy and health measures in patients with plaque psoriasis during a 12-week period, regardless of a patient's psoriatic arthritis status at baseline.

Psoriasis

Psoriasis Treatment Ixekizumab Safe for Cardiovascular Health

By April 17, 2018

Biologic therapies for psoriasis may have an impact on cardiovascular parameters, potentially resulting in the occurrence of major adverse cardiovascular events.

Psoriasis

Differentiating Responders to Systemic Therapies From Nonresponders With Psoriasis

By April 12, 2018

Treatment decisions are difficult to make in psoriasis patients, given the paucity of objective tools for evaluation of response to treatment.

Psoriasis

Shortness of Breath in Psoriasis May Be Linked to Reduced FEV1

By April 11, 2018

Psoriasis is a chronic inflammatory systemic disease associated with several comorbid conditions, including chronic obstructive pulmonary disease and asthma.

Psoriasis

Psoriasis Disease Perceptions Differ Between Patients, Dermatologists

By April 09, 2018

Further communication between the patient and provider is needed to better understand the impact of disease severity and treatment.

Psoriasis

Guselkumab More Effective Than Adalimumab for Reduction of Psoriasis Symptoms

By April 09, 2018

Investigators analyzed data from the first year of VOYAGE 1, an ongoing, phase 3, double-blind, controlled trial of patients with moderate to severe psoriasis.

Psoriasis

Brodalumab Effective for Reduction of Itch Associated With Psoriasis

By April 05, 2018

In AMAGINE-1/2/3, brodalumab improved PSI total and itch scores from week 2 through 12, compared with placebo (both P <.001).

Psoriasis

Screening Tool Helps Identify Psoriasis Patients In Need of Rheumatology Consult

By April 04, 2018

Diagnosis of PsA was made by rheumatologists using CASPAR criteria, and univariate associations between the items and PsA diagnosis were analyzed.

Psoriasis

Biologic Therapies Generally Safe in Psoriasis with Comorbid Cirrhosis

By March 28, 2018

The investigators sought to examine adverse events and outcome parameters in a group of patients with psoriasis who were treated with biologics and had received a diagnosis of cirrhosis.

Psoriasis

Ilumya Approved for Moderate-to-Severe Plaque Psoriasis

By March 27, 2018

The FDA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program.

Psoriasis

Brodalumab Has Comparable Efficacy to Ustekinumab in Plaque Psoriasis

By March 23, 2018

Nearly twice as many patients treated with brodalumab 210 mg Q2W achieved PASI 100 or complete clearance at week 12 compared with ustekinumab-treated patients, with the differences most evident in those in whom prior biologics had failed.

Psoriasis

Risk for Cardiovascular Events Lower in Psoriasis Treated With TNFi

By March 21, 2018

Patients in the TNFi arm had a significantly lower risk for CV events compared with those in the phototherapy arm.

Sign up for Newsletters